Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083327 | 0.90 | TRPV1 (0.61) | TRPV1RXFP1 | |
| SCHEMBL14083325 | 0.89 | TRPV1 (0.48) | TRPV1KDRKDM4ERXFP1 | |
| SCHEMBL14083235 | 0.88 | TRPV1 (0.56) | TRPV1MAPTKDRABL1TDP1 | |
| SCHEMBL14083321 | 0.88 | RXFP1 (0.46) | TRPV1MAPTKDM4ETDP1RXFP1 | |
| SCHEMBL14083331 | 0.87 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL14083329 | 0.86 | TRPV1 (0.51) | TRPV1MAPTKDRRXFP1 | |
| SCHEMBL14083179 | 0.86 | KDR (0.55) | TRPV1MAPTKDRABL1TDP1 | |
| SCHEMBL14083330 | 0.86 | TRPV1 (0.48) | TRPV1RXFP1 | |
| SCHEMBL14083341 | 0.85 | RXFP1 (0.64) | TRPV1MAPTKDRABL1RXFP1 | |
| SCHEMBL14083323 | 0.84 | GHSR (0.45) | TRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MAPT 2822/4885KDR 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.